BioWorld

May 5, 2003

Repligen Raises $12.5 Privately To Advance Secretin Program

Repligen Corp. raised $12.5 million through a private placement and will use the funds in part for its Phase III product, secretin, also called RG1068. (BioWorld Today) Read More

RNA Tools Company Ambion Gets $10.5 Million In Private Placement

Pennsylvania Team Makes Eggs,Seems To Abrogate Sacrosanct Embryonic Stem Cells Barrier

Strong, Predictable Patent Office Needed By Biotech, Pharma Firms

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 12, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld Science

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...